Omicron 2, there is still no evidence that it holes more vaccines. The situation is different for monoclonal antibodies. This was pointed out by Marco Cavaleri, head of Vaccines and Covid-19 therapeutic products of the European Medicines Agency EMA, today during the periodic briefing with the press. “There is currently no indication that the immune leak after vaccination is significantly different with Omicron BA.2 – he points out – while the activity pattern of monoclonal antibodies can vary significantly with each Omicron sub-variant.”
“While many European countries are lifting” anti-Covid “restrictions and returning to normal life before the pandemic, we see infection rates rising again in some Member States after the steady decline we have seen in recent weeks. This “trend” apparently appears to be driven by the increasing circulation of Omicron’s BA.2 sub-variant “, known as Omicron 2,” which appears to be more transmissible than other variants of Sars-CoV-2. It is the picture drawn by Cavaleri.
“We are continuing to evaluate the data on the efficacy of anti-Covid vaccines and treatments against Omicron and its sub-variants. Faced with the growth in infection rates, it is important to underline – he highlights – that vaccination continues to offer high protection. against hospitalization and death due to Covid, although according to some studies there is a certain reduction in protection from serious illness over time at least in the most vulnerable populations “.
In light of all this, “we continue to urge all citizens to be vaccinated and to receive the booster – urges Cavaleri – if they are in the suitable category to receive it”. In fact, a pattern is observed: “Countries with high vaccination rates are reporting significantly lower mortality and hospitalization rates”.
As for the Russian “Sputnik vaccine” against Covid-19 “it has undergone a rolling review”, the cyclical review process of the European Medicines Agency Ema, “but there are currently no activities” underway by the EU regulatory body. “in that review cycle. Apart from this” vaccine “we have no other Russian products under evaluation”, and therefore at this time “we have no contact with the Russian authorities”. This was explained by Fergus Sweeney, head of EMA’s clinical studies and production, responding to journalists during the periodic update with the press.
#Omicron #Ema #evidence #vaccines #holes